SCHEMBL31358729

SCHEMBL31358729

Cc1ccc(Cl)cc1-c1ccc(C=C2C(=O)c3ccccc3C2=O)o1

nearest known ligand 0.69

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAPT P10636 13/20 0.69
POLB P06746 11/20 0.69
MEN1 O00255 11/20 0.69
KMT2A Q03164 11/20 0.69
ALDH1A1 P00352 10/20 0.69
L3MBTL1 Q9Y468 5/20 0.69
KDM4E B2RXH2 4/20 0.69
CTDSP1 Q9GZU7 2/20 0.69
PPM1G O15355 1/20 0.59
PTPN1 P18031 1/20 0.59
PTPN7 P35236 1/20 0.59
PTPN5 P54829 1/20 0.59
PTPRO Q16827 1/20 0.59
PTPN22 Q9Y2R2 1/20 0.59
HPGD P15428 7/20 0.56
NPSR1 Q6W5P4 6/20 0.56
TDP1 Q9NUW8 3/20 0.56
PKM P14618 3/20 0.56
MAPK1 P28482 1/20 0.56
NTSR1 P30989 1/20 0.56

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL31358701 0.87 MAPT (0.65) MAPTPOLBMEN1KMT2AALDH1A1
SCHEMBL31358707 0.84 MAPT (0.65) MAPTPOLBMEN1KMT2AALDH1A1
SCHEMBL31358757 0.81 MEN1 (1.00) MAPTPOLBMEN1KMT2AALDH1A1
SCHEMBL31358711 0.81 MAPT (0.64) MAPTPOLBMEN1KMT2AALDH1A1
SCHEMBL31358866 0.80 KMT2A (0.69) MAPTPOLBMEN1KMT2AALDH1A1
SCHEMBL31358792 0.79 JAK2 (0.60) MAPTPOLBMEN1KMT2AALDH1A1
SCHEMBL31358767 0.79 MAPT (0.58) MAPTPOLBMEN1KMT2AALDH1A1
SCHEMBL31358709 0.79 MEN1 (0.64) MAPTPOLBMEN1KMT2AALDH1A1
SCHEMBL31358693 0.79 AKT1 (0.58) MAPTPOLBMEN1KMT2AALDH1A1
SCHEMBL27330465 0.78 KDM4E (0.58) MAPTPOLBMEN1KMT2AALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20250026741-A1 INHIBITORS OF THE ONCOGENIC SHP2 PHOSPHATASE AND USES THEREOF Sanford Burnham Prebys Medical Discovery Institute 2025-01-23 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20250026741-A1 INHIBITORS OF THE ONCOGENIC SHP2 PHOSPHATASE AND USES THEREOF PTPN18, PTPN7, PTPN1 MAPT 4688/4885POLB 3743/4885MEN1 2467/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.